Master Protocol
For Treatment Of
Non-Small Cell
Lung Cancer
(Lung-MAP)

Our mission is to accelerate the development of cancer therapies by improving clinical trial design.

Lung-MAP, a Master Protocol for Treatment of Non-Small Cell Lung Cancer, is a groundbreaking multi-center clinical trial that uses a multi-sub-study, targeted screening approach to match patients, based on their unique tumor profiles, with sub-studies testing investigational new treatments. Specifically, Lung-MAP uses cutting-edge genomic profiling to determine the genomic alterations, or mutations, which may drive the growth of their cancer.

Based on those results, patients are matched to either a biomarker or a non-matched sub-study. The “non-match” sub-study includes all screened patients not eligible for any of the biomarker-driven sub-studies. The various sub-studies test therapies suspected to target the genomic alterations or mutations found to be driving the growth of patients’ cancer. Instead of undergoing multiple diagnostic tests to determine eligibility for many different studies, enrollees are tested for genomic alterations just once, according to a master screening protocol, LUNGMAP.

Learn More